Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCY-641
- Development stage
- Discontinued
- Lead developer
- Scynexis
- Modality
- Small Molecules, Peptides
- Administration
- Ophthalmic
01
Overview
SCY-641 is a cyclophilin inhibitor and cyclosporine derivative developed by SCYNEXIS. It was primarily investigated for the treatment of ophthalmic diseases, specifically keratoconjunctivitis sicca (KCS or "dry eye") in dogs. The compound was licensed to Dechra Pharmaceuticals for worldwide animal health applications in 2012, but the agreement was terminated in 2015 (effective May 2016), with all rights returning to SCYNEXIS. SCY-641 is part of SCYNEXIS's cyclophilin inhibitor platform, which also includes SCY-635. The drug's development was supported by a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. Federal Government for its potential in treating ophthalmic diseases.
- Other names
- cyclosporine derivative
Beyond the preview
Go deeper on SCY-641.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCY-641.